Dorsavi Ltd. · ASX:DVL
Dorsavi — Investor Presentation (April 2015)
33 slides from Dorsavi's investor presentation, Apr 14, 2015
Slide 1: Investor Update April 2015
For personal use only Investor Update April 2015 1
Slide 2: Company overview (Operational)
Company overview (Operational) For personal use only • Patented technology providing accurate movement analysis • Products across three market segments (Clinical, OH&S and Sport) • Clearance for sale in the major markets: US/Canada, Europe & ANZ • Direct sales force in US, UK and Aust • Sales moment
Slide 3: Company overview (Investment)
Company overview (Investment) For personal use only 2015 H1 Financial Results 700 dorsaVi Limited ASX:dvl 600 Share price (issue $0.40) $0.325 (Fri 10th April close) 500 Shares on issue 121,250,000 170 400 Market capitalisation $39.4 million Sales H2 $ Thousand 172 616 300 H1 Free float 41,250,000 2
Slide 4: Medical grade wearables
Medical grade wearables For personal use only • Wearables without valid clinical data will not be accepted by regulators • Need to meet stringent system req’s • Valid & reliable data • Clinical safety and effectiveness • Crisis in pain management • Escalating costs • Urgent need for effective outcom
Slide 5: Samples of wearable data
Samples of wearable data Running data from a typical consumer wearable For personal use only consumer Acceleration Vector data • Limited data from well known wearable • Lower quality data with poor reliability and validity • Minimal clinical evidence 5
Slide 6: dorsaVi's expert data
dorsaVi’s expert data Running data from dorsaVi’s ViPerform dorsaVi For personal use only consumer Acceleration Vector data • Defining normal, abnormal and elite patterns • Unsurpassed level of data from mobile wearable • Configurable to multiple applications 6
Slide 7: Quality data drives our market opportunities
Quality data drives our market opportunities For personal use only Usage Growth – dorsaVi sessions performed • The more data we get the more valuable we become 20000 • Best positioned company globally for 18000 16000 quality human movement data 14000 12000 • Major Consumer companies asking for runni
Slide 8: Three business products
Three business products For personal use only OH&S Clinical Sport 8
Slide 9: OH&S
OH&S For personal use only • Unique data on worker’s movement patterns • Determines high risk activities • Interventions involving: • job assessment • equipment design changes • pre employment screening • Better decisions based on fact, not opinion • Scalable across industry and across countries 9
Slide 10: Size of the OHS market
Size of the OHS market For personal use only COSTS IN THE UNITED STATES $250B 250 $219B • Clients have an immediate need 200 $187B • Large untapped market • Offering resonates with decision makers 150 • Market characterized by 1000’s of major 100 $63B corporates & their insurers 50 • Opportunity to
Slide 11: Integrated offering drives revenue per client
Integrated offering drives revenue per client For personal use only • Audit QMS and work practices to identify problems or potential problems • Build & Maintain an appropriate Quality Management System (QMS) • Understand and pin point any Manual Handling risk • Find solutions to reduce or eliminate
Slide 12: Driving scale through major partners
Driving scale through major partners For personal use only •• dorsaVi focus $61B cost on analytics in Australia ($250B US) •• Outsourced Tested and sales provenfunction model for scale Sales Operations Analytics •• 50% partner Scale within generated clients (Aurora) Outsourced Outsourced •• Scale Sc
Slide 13: Making a huge commercial difference to our clients
Making a huge commercial difference to our clients For personal use only • Assessed specific work task 72 injuries Q1 2014 • Used dorsaVi sensors to identify risk & plan changes • Third party – pre employment screening 1 injury Q1 2015 • Consumable revenue from 300+ screenings to dorsaVi • Optimised
Slide 14: OHS – Looking forward
OHS – Looking forward For personal use only • Growing referrals from global insurers • Major corporates coming on board • Increasing average deal sizes • Assessments leading to solution projects • Establishing OHS entry into the US and UK 14
Slide 15: Clinical
For personal use only Clinical 15
Slide 16: Low Back Pain is a major medical market
Low Back Pain is a major medical market For personal use only COSTS IN THE UNITED STATES $250B 250 • Large market with many barriers $219B $187B $194B • dorsaVi well positioned: 200 • Regulatory clearance 150 • Very positive Clinical trial data 100 $63B • Clear reimbursement plan 50 • Payers want a
Slide 17: The Clinical Course of low back Pain – Why it costs $194B p.a.
Cost The Clinical Course of low back Pain – Why it costs $194B p.a. $US /patient Long term disabled 45 to 72% of people will have recurrences within 12 months Spinal Cord Opioids dependence For personal use only . Stimulation $50k Physio/Chiro Cumulative: $720k $800k (35% taken out) Opioids Repeat S
Slide 18: Compelling Clinical data in Chronic Low Back Pain
45% Reduction in Pain Compelling Clinical data in For personal use only Chronic Low Back Pain * Abstract presented by Dr Peter Kent, International Low Back Forum, Brazil Oct 2014 (P<0.001) • A multi-center, cluster randomized, placebo- controlled trial 73% Increase in Function • Clinical trial under
Slide 19: dorsaVi impacts where costs can be best managed
Cost dorsaVi impacts where costs can be best managed $US /patient For personal use only $800k . dorsaVi . $400k Impact . . $100k . . . 3m 6m 12 m 2 years 3 years 4 years Acute Pain Chronic Pain Repeat Spinal Cord Chronic Surgery 3 months > 3 months Surgery Stimulation Management 1-2 years 2-3 years
Slide 20: The patient reports the same level of pain but 3-6 times more active
The patient reports the same level of pain but 3-6 times more active Why Payers For personal use only will pay 550 mins 533 mins Day 1 Day 28 390 mins • Movement data is more 310 mins sensitive than current Pain score = 6 (VAS) 260 mins 245 mins outcome measures • Patient is getting better 60 mins 6
Slide 21: Reimbursement Strategy
Reimbursement Strategy For personal use only Use Existing Code Generate Own Code Australia EMG code $149 per session MSAC process – targeting 2017 Pathway to generate own codes in: 2 existing codes identified for potential use: Diagnostic schedule (assessment and monitoring) 1) Gait analysis UK Proc
Slide 22: Clinical
Clinical For personal use only • Market growth driven through validated protocols • Annuity model where clinics pay $5,000 – 7,500 p.a. per unit (+ consumables) • Thought leaders taking up ViMove (US (New York), UK (Harley St) and Aust (OPSMC)) • Retention rate high • Opportunity for strong growth t
Slide 23: Current global penetration – 150+ devices
Current global penetration – 150+ devices For personal use only 100 devices (Aust) 40 devices (Europe) 10 devices (USA) 23
Slide 24: Momentum building – Harley Street, London
Momentum building – Harley Street, London For personal use only 24
Slide 25: Sports
For personal use only Sports 25
Slide 26: Sports
Sports For personal use only • Sports providing great PR and validation • Drives new cutting edge innovation (clinical and OHS relevant) • A number of commercial injury prevention projects • Unique insights provided to world’s biggest sporting brands • Provides profile to later leverage into consume
Slide 27: Being used for injury prevention and assessment
Being used for injury prevention and For personal use only assessment • Hamstring – AFL, NFL, NBA, EPL • Knee – AFL, NFL, NBA, EPL • Low Back – AIS Rowing, Cricket • Running – EPL, AFL, NFL, NBA • Return to play decisions - AFL, NFL 27
Slide 28: Knee prevention example
Knee prevention example For personal use only 28
Slide 29: Knee prevention program across international major sports
Knee prevention program across international major sports For personal use only 29
Slide 30: Leading groups across all three sectors
Leading groups across all three sectors For personal use only OH&S ? CLINICAL SPORTS 30
Slide 31: Product expansion coming
Product expansion coming For personal use only • 5.9 Release • New sensors for new applications • Faster software • Sporting, cervical, wrist • Intuitive & personalised reporting • Smaller, lighter, talks with phone • Self directed therapy with clinical evidence • OHS & clinical trial market • Value
Slide 32: Upcoming milestones/newsflow
Upcoming milestones/newsflow For personal use only • OHS scale • Within clients (Crown, Orora, BP, Sodexo) • Across clients (Insurers & Payers) • Across geographies - UK and US • Clinical trial publication • Brand refresh & Major software release (5.9) • Major clinical PT group in the US • Commercia
Slide 33: Board and senior management
Board and senior management Board For personal use only Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia AC MBE BCom CPA GAICD BSc (Hons), MBA, PhD BSc (Eng)(Hons), MSc FAICD (Biomed. Eng), Dip (Mktg), FAICD Director &